Axon Enterprise, Inc. (NASDAQ:AXON) Holdings Boosted by Vaughan Nelson Investment Management L.P.

Vaughan Nelson Investment Management L.P. lifted its stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 18.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 104,587 shares of the biotechnology company's stock after purchasing an additional 16,230 shares during the period. Vaughan Nelson Investment Management L.P. owned about 0.14% of Axon Enterprise worth $27,019,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. increased its position in Axon Enterprise by 11.7% in the 1st quarter. BlackRock Inc. now owns 8,329,479 shares of the biotechnology company's stock valued at $1,872,883,000 after acquiring an additional 870,481 shares during the period. State Street Corp increased its position in Axon Enterprise by 22.6% in the 2nd quarter. State Street Corp now owns 2,915,214 shares of the biotechnology company's stock valued at $568,817,000 after acquiring an additional 538,119 shares during the period. Capital International Investors increased its position in Axon Enterprise by 605.2% in the 1st quarter. Capital International Investors now owns 2,660,634 shares of the biotechnology company's stock valued at $366,449,000 after acquiring an additional 2,283,343 shares during the period. Sands Capital Management LLC increased its position in Axon Enterprise by 31.1% in the 3rd quarter. Sands Capital Management LLC now owns 2,612,305 shares of the biotechnology company's stock valued at $519,823,000 after acquiring an additional 619,179 shares during the period. Finally, Wellington Management Group LLP increased its position in Axon Enterprise by 3.3% in the 3rd quarter. Wellington Management Group LLP now owns 1,956,022 shares of the biotechnology company's stock valued at $389,229,000 after acquiring an additional 62,324 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. The Goldman Sachs Group boosted their price target on Axon Enterprise from $297.00 to $339.00 and gave the company a "buy" rating in a research report on Wednesday, February 28th. Argus initiated coverage on Axon Enterprise in a research report on Wednesday, March 13th. They set a "buy" rating and a $380.00 target price on the stock. JMP Securities boosted their target price on Axon Enterprise from $250.00 to $285.00 and gave the stock a "market outperform" rating in a research report on Tuesday, February 6th. Needham & Company LLC boosted their target price on Axon Enterprise from $240.00 to $315.00 and gave the stock a "buy" rating in a research report on Wednesday, February 28th. Finally, Robert W. Baird boosted their target price on Axon Enterprise from $260.00 to $300.00 and gave the stock an "outperform" rating in a research report on Thursday, February 22nd. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Axon Enterprise currently has a consensus rating of "Moderate Buy" and a consensus target price of $301.73.

Axon Enterprise Price Performance

AXON stock traded up $3.07 on Friday, reaching $309.90. The company had a trading volume of 183,544 shares, compared to its average volume of 440,078. Axon Enterprise, Inc. has a 1 year low of $175.37 and a 1 year high of $325.63. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.66 and a current ratio of 3.00. The company's fifty day moving average is $291.26 and its 200 day moving average is $250.97. The company has a market cap of $23.39 billion, a P/E ratio of 134.74 and a beta of 0.93.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.29. Axon Enterprise had a return on equity of 14.11% and a net margin of 11.14%. The firm had revenue of $432.14 million for the quarter, compared to analyst estimates of $418.97 million. On average, research analysts forecast that Axon Enterprise, Inc. will post 2.43 earnings per share for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.